Alleviating fear and suffering when a cure is not possible. (ASCO Connection)
Bristol-Myers Squibb announced that the FDA expanded indications for dasatinib (Sprycel) to include use in combination with chemotherapy to treat patients 1 year and older with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia.
Know someone who’s trying to quit smoking to start the new year? Here’s how you can help. (American Cancer Society)
A form of artificial intelligence showed potential for predicting the type and severity of symptoms patients may have during treatment for cancer. (University of Surrey, PLoS One)
Treatment based, in part, on a patient’s sex may help improve outcomes in glioblastoma. (Washington University in St. Louis, Science Translational Medicine)
An ongoing clinical trial will evaluate the ability of a breath test to diagnose multiple types of cancer. (Cancer Research UK)
The American Society of Clinical Oncology will co-host a global conference on technology innovation in cancer.
Opioid addiction in cancer survivors might be more difficult to treat than the cancer. (New England Journal of Medicine; subscription required for full access)
Immune checkpoint inhibitors work equally well in men and women with advanced cancers, according to a meta-analysis of multiple studies. (JAMA Oncology)
As the number of clinical trials of new cancer immunotherapies increases, a word of caution about rushing to evaluate the new drugs without a thorough understanding of how they work. (Yale Cancer Center)
last updated
Source: MedicalNewsToday.com
